แนวคิดหลัก
Strategies to overcome resistance to ALK inhibitors in NSCLC are crucial for improving patient outcomes.
สถิติ
ALK rearrangements detected in 3-7% of advanced NSCLC
5 FDA-approved ALK tyrosine kinase inhibitors
ALK fusions are therapeutic targets across multiple tumors
คำพูด
"Strategies to overcome resistance to currently available ALK inhibitors are urgently needed."
"Given the variety of resistance mechanisms, tailormade approaches are required for disease control."